ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

ClinicalTrials.gov ID: NCT04979442

Public ClinicalTrials.gov record NCT04979442. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients With Dedifferentiated Liposarcoma

Study identification

NCT ID
NCT04979442
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Rain Oncology Inc
Industry
Enrollment
175 participants

Conditions and interventions

Interventions

  • RAIN-32 Drug
  • Trabectedin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 13, 2021
Primary completion
Sep 30, 2023
Completion
Sep 30, 2023
Last update posted
Jan 13, 2025

2021 – 2023

United States locations

U.S. sites
22
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
Stanford Cancer Center Palo Alto California 94304
Sarcoma Oncology Research Center, LLC Santa Monica California 90403
UCLA Department of Medicine - Hematology/ Oncology Santa Monica California 90404
CU Anschutz Medical Campus, Anschutz Cancer Pavilion Aurora Colorado 80045
Mayo Clinic Florida Jacksonville Florida 32224
University of Miami Hospital & Clinics - Sylvester Comprehensive Cancer Center Miami Florida 33136
H. Lee Moffitt Cancer Center & Research Institute Tampa Florida 33612
Northwestern Memorial Hospital Chicago Heights Illinois 60611
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland 21231
Massachusetts General Hospital Boston Massachusetts 02114
Dana Farber Cancer Institute Boston Massachusetts 02215-5450
University of Michigan Ann Arbor Michigan 48109
Washington University School of Medicine St Louis Missouri 63110
Columbia University Medical Center New York New York 10032
Memorial Sloan-Kettering Cancer Center New York New York 10065
Duke University School of Medicine, Duke Cancer Institute Durham North Carolina 27710
Cleveland Clinic Foundation Cleveland Ohio 44195
The James Cancer Hospital and Solove Research Institute Columbus Ohio 43210
Oregon Health & Science University Portland Oregon 97239
Abramson Cancer Center at Pennsylvania Hospital Philadelphia Pennsylvania 19106
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232
MD Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04979442, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 13, 2025 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04979442 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →